AACE convened a conference to review factors associated with cancer development in people with obesity and diabetes and to discuss the possible cancer risk of antihyperglycemic medications.
AACE/ACE Position Statement on the Association of SGLT-2 Inhibitors and Diabetic Ketoacidosis © 2016
Recent reports of diabetic ketoacidosis (DKA) occur-ring in conjunction with sodium glucose-cotransporter 2 (SGLT-2) inhibitor therapy have raised concerns that these agents may increase the risk of DKA, especially among patients
Among the more than 20 million Americans whohave diabetes, approximately 30% of the cases are undi-agnosed (1).
Learn about our updated guideline for the care and management of people with or at risk for diabetes mellitus. The guideline features 170 updated and new evidence-based clinical practice recommendations for diabetes at every stage, including prevention, diagnosis, and treatment.